Imaging Technology

JULY 28, 2023

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

Clinic 84

Clinic Diagnostic Radiopharmaceuticals Radiation 84

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 95

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 95

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. “PET Clinical correlation, which may include histopathological evaluation, is recommended.

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93